Transient neonatal diabetes mellitus due to de novo mutation in KCNJ11 gene
DOI:
https://doi.org/10.18203/2349-3291.ijcp20251881Keywords:
NDM, TNDM, KCNJ11, Monogenic diabetesAbstract
Neonatal diabetes mellitus (NDM) is a rare monogenic diabetes that usually presents in first 6 months of life. Activating mutations in KCNJ11 gene encoding Kir6.2 subunit of ATP-sensitive potassium (KATP) channel cause either transient NDM (TNDM) or permanent NDM (PNDM). A month-old male presenting with diabetic ketoacidosis was managed initially with intravenous (IV) fluids and IV insulin administration and subsequently started on subcutaneous insulin therapy on resolution of ketoacidosis. C-peptide level at diagnosis was 0.51 ng/ml and sanger sequencing analysis of the ABCC8, KCNJ11, INS and EIF2AK3 genes identified a heterozygous missense mutation p.R50Q in KCNJ11 gene. Successful transition to oral sulfonylurea therapy was made with maintenance of euglycemia and remission of NDM was witnessed at 5 months of age. A diagnosis of TNDM due to mutation in Kir6.2 subunit of K-ATP channel was made, supervised discontinuation of sulfonylurea therapy performed and the 50 percent risk of relapse of DM during adolescence or adulthood was explained to the family.
Metrics
References
Letourneau LR, Carmody D, Wroblewski K, Denson AM, Sanyoura M, Naylor RN, et al. Diabetes Presentation in Infancy: High Risk of Diabetic Ketoacidosis. Diabetes Care. 2017;40(10):e147-8. DOI: https://doi.org/10.2337/dc17-1145
Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue K; International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2006-2007. The diagnosis and management of monogenic diabetes in children. Pediatr Diabetes. 2006;7(6):352-60. DOI: https://doi.org/10.1111/j.1399-5448.2006.00217.x
Grulich-Henn J, Wagner V, Thon A, Schober E, Marg W, Kapellen TM, et al. Entities and frequency of neonatal diabetes: data from the diabetes documentation and quality management system (DPV). Diabet Med. 2010;27(6):709-12. DOI: https://doi.org/10.1111/j.1464-5491.2010.02965.x
Lemelman MB, Letourneau L, Greeley SAW. Neonatal diabetes mellitus: an update on diagnosis and management. Clin Perinatol. 2018;45(1):41-59. DOI: https://doi.org/10.1016/j.clp.2017.10.006
Temple IK, Shield JP. Transient neonatal diabetes, a disorder of imprinting. J Med Genet. 2002;39(12):872-5. DOI: https://doi.org/10.1136/jmg.39.12.872
De Franco E, Flanagan SE, Houghton JAL, Lango Allen H, Mackay DJ, Temple IK, et al. The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study. Lancet (London, England). 2015;386(9997):957-63. DOI: https://doi.org/10.1016/S0140-6736(15)60098-8
De León DD, Stanley CA. Permanent Neonatal Diabetes Mellitus. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K (eds). GeneReviews®. Seattle (WA): University of Washington, Seattle,1993-2017. 2008.
Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM. Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci U S A. 2004;101:17539-44. DOI: https://doi.org/10.1073/pnas.0404756101
Gloyn AL, Reimann F, Girard C, Edghill EL, Proks P, Pearson ER, et al. Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum Mol Genet 2005;14:925-34. DOI: https://doi.org/10.1093/hmg/ddi086
Beardsall K, Pesterfield CL, Acerini CL. Neonatal diabetes and insulin pump therapy. Arch Dis Child Fetal Neonatal Ed. 2011;96:223-4. DOI: https://doi.org/10.1136/adc.2010.196709
Park JH, Kang JH, Lee KH, Kim NH, Yoo HW, Lee DY, et al. Insulin pump therapy in transient neonatal diabetes mellitus. Ann Pediatr Endocrinol Metab. 2013;18:148-51. DOI: https://doi.org/10.6065/apem.2013.18.3.148
Rabbone I, Barbetti F, Marigliano M, Bonfanti R, Piccinno E, Ortolani F, et al. Successful treatment of young infants presenting neonatal diabetes mellitus with continuous subcutaneous insulin infusion before genetic diagnosis. Acta Diabetol. 2016;53(4):559-65. DOI: https://doi.org/10.1007/s00592-015-0828-7
Lau E, Correia C, Freitas P, Nogueira C, Costa M, Saavedra A, et al. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea. Arch Endocrinol Metab. 2015;59(6):559-61. DOI: https://doi.org/10.1590/2359-3997000000076
Carmody D, Bell CD, Hwang JL, Dickens JT, Sima DI, Felipe DL, et al. Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons. J Clin Endocrinol Metab. 2014;99(12):E2709-14. DOI: https://doi.org/10.1210/jc.2014-2494
Katanic D, Vorgučin I, Hattersley A, Ellard S, Houghton JAL, Obreht D, et al. A successful transition to sulfonylurea treatment in male infant with neonatal diabetes caused by the novel abcc8 gene mutation and three years follow-up. Diabetes Res Clin Pract. 2017;129:59-61. DOI: https://doi.org/10.1016/j.diabres.2017.04.021
Le Bourgeois F, Beltrand J, Baz B, Julla JB, Riveline JP, Simon A, et al; TNDM Long-Term Follow-Up Study Group. Long-term Metabolic and Socioeducational Outcomes of Transient Neonatal Diabetes: A Longitudinal and Cross-sectional Study. Diabetes Care. 2020;43(6):1191-9. DOI: https://doi.org/10.2337/dc19-0324
Downloads
Published
How to Cite
Issue
Section
